Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients - Full Text View

Sponsor:	Weill Medical College of Cornell University
Information provided by:	Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:	NCT00909363

Purpose

The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.

Condition	Intervention	Phase
Wiskott-Aldrich Syndrome Thrombocytopenia Bleeding	Drug: Promacta (eltrombopag)	Phase II

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Pathobiology of Thrombocytopenia and Bleeding in Patients With Wiskott-Aldrich Syndrome

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency hemophilia MYH9-related disorder Wiskott-Aldrich syndrome Help Me Understand Genetics

Drug Information available for: Eltrombopag

U.S. FDA Resources

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:

To increase platelet counts of WAS and XLT patients to above 30,000/ul. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo. [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	50
Study Start Date:	June 2009
Estimated Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)

Intervention Details:

Patients will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP.

Detailed Description:

Wiskott Aldrich Syndrome is an X-linked disease characterized by immunodeficiency, eczema and thrombocytopenia; a milder form of the disease known as X-Linked thrombocytopenia also exists. The thrombocytopenia in both WAS and XLT is characterized by: severe thrombocytopenia with platelet counts frequently less than 10-30,000/ul; small platelets which may be dysfunctional; and, as a result, a high rate of serious bleeding including intracranial hemorrhage.

Because eltrombopag has been shown to be remarkably efficacious in substantially increasing platelet counts in a high percentage of ITP patients, this study seeks to effectively treat patients who exhibit similar pathologies, as well as evaluate the state of platelets in patients with WAS and relate it to clinical bleeding. It also aims to demonstrate whether eltrombopag administered daily will enhance stem cell function, increase platelet production and platelet count, and reduce bleeding in patients with WAS.

Eligibility

Ages Eligible for Study:	3 Months to 80 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

In order to be eligible for study entry, subjects must comply with the following:

Males from 3 months old to 80 years old
Signed written informed consent obtained prior to study entry
Clinical diagnosis of WAS or XLT
Platelet levels less than 100 x 109/L
Adequate renal and hepatic function (creatinine and bilirubin less than or equal to 1.5 x IULN, AST and ALT less than or equal to 2.5 x IULN)

Exclusion Criteria:

Any patient is ineligible for study entry if he/she:

Over the age of 80
Women (only males are eligible)
fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study or until at least 6 months after treatment
Aspirin, aspirin-containing compounds, salicylates, non-steroidal anti-inflammatory medications (NSAIDS), clopidogrel or ticlopidine, warfarin or other vitamin K antagonists, unfractionated or low molecular heparin within 7 days of first infusion
Red blood cell transfusion in the past four weeks
Elevated (> 1.5 x ULN) prothrombin time (PT) or partial thromboplastin time (PTT)
New York Heart Classification III or IV heart disease. Other severe cardiovascular or cardiopulmonary disease, including COPD.
Known HIV infection, hepatitis B or C infection
Any infection requiring antibiotic treatment within 3 days
Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma skin cancers and carcinoma in situ of the cervix

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00909363

Contacts

Contact: James B Bussel, MD

212-746-3474

jbussel@med.cornell.edu

Locations

United States, New York
Weill Cornell Medical College	Recruiting
New York, New York, United States, 10065

Sponsors and Collaborators

Weill Medical College of Cornell University

Investigators

Principal Investigator:

James B Bussel, MD

Weill Medical College of Cornell University

More Information

No publications provided

Responsible Party:	James Bussel, MD, Weill Cornell Medical College
ClinicalTrials.gov Identifier:	NCT00909363 History of Changes
Other Study ID Numbers:	0801009600
Study First Received:	May 27, 2009
Last Updated:	September 28, 2010
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Hemorrhage
Thrombocytopenia
Wiskott-Aldrich Syndrome
Pathologic Processes
Blood Platelet Disorders
Hematologic Diseases
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders

Hemorrhagic Disorders
Lymphopenia
Leukopenia
Leukocyte Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Immunologic Deficiency Syndromes
Immune System Diseases

ClinicalTrials.gov processed this record on February 09, 2012